184 related articles for article (PubMed ID: 35107655)
21. Health related quality of life in Japanese men with localized prostate cancer treated with current multiple modalities assessed by a newly developed Japanese version of the Expanded Prostate Cancer Index Composite.
Kakehi Y; Takegami M; Suzukamo Y; Namiki S; Arai Y; Kamoto T; Ogawa O; Fukuhara S
J Urol; 2007 May; 177(5):1856-61. PubMed ID: 17437836
[TBL] [Abstract][Full Text] [Related]
22. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study.
Mazariego CG; Egger S; King MT; Juraskova I; Woo H; Berry M; Armstrong BK; Smith DP
BMJ; 2020 Oct; 371():m3503. PubMed ID: 33028540
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
[TBL] [Abstract][Full Text] [Related]
24. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
25. A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.
Klotz L; Loblaw A; Siemens R; Ouellette P; Kapoor A; Kebabdjian M; Zhang L; Saad F;
J Urol; 2018 Aug; 200(2):335-343. PubMed ID: 29534997
[TBL] [Abstract][Full Text] [Related]
26. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A;
Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237
[TBL] [Abstract][Full Text] [Related]
27. Androgen Deprivation Therapy and Mental Health: Impact on Depression and Cognition.
Izard JP; Siemens DR
Eur Urol Focus; 2020 Nov; 6(6):1162-1164. PubMed ID: 31911085
[TBL] [Abstract][Full Text] [Related]
28. Long-term quality of life after radical prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial.
Sterba KR; Swartz RJ; Basen-Engquist K; Black PC; Pettaway CA
Support Care Cancer; 2011 Aug; 19(8):1117-24. PubMed ID: 20499107
[TBL] [Abstract][Full Text] [Related]
29. Predictors of depression, anxiety and quality of life in patients with prostate cancer receiving androgen deprivation therapy.
Chipperfield K; Fletcher J; Millar J; Brooker J; Smith R; Frydenberg M; Burney S
Psychooncology; 2013 Oct; 22(10):2169-76. PubMed ID: 23483679
[TBL] [Abstract][Full Text] [Related]
30. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
31. Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer.
Lilleby W; Stensvold A; Dahl AA
Acta Oncol; 2016 Jul; 55(7):807-13. PubMed ID: 26959297
[TBL] [Abstract][Full Text] [Related]
32. Androgen deprivation therapy and radiation for prostate cancer-cognitive impairment, sleep, symptom burden: a prospective study.
Tulk J; Rash JA; Thoms J; Wassersug R; Gonzalez B; Garland SN
BMJ Support Palliat Care; 2023 Dec; 13(e2):e454-e463. PubMed ID: 34330793
[TBL] [Abstract][Full Text] [Related]
33. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
Segal RJ; Reid RD; Courneya KS; Malone SC; Parliament MB; Scott CG; Venner PM; Quinney HA; Jones LW; D'Angelo ME; Wells GA
J Clin Oncol; 2003 May; 21(9):1653-9. PubMed ID: 12721238
[TBL] [Abstract][Full Text] [Related]
34. Symptom experiences of older adults during treatment for metastatic prostate cancer: A qualitative investigation.
Parthipan M; Feng G; Toledano N; Donison V; Breunis H; Sudharshan A; Emmenegger U; Finelli A; Warde P; Soto-Perez-de-Celis E; Krzyzanowska M; Matthew A; Clarke H; Mina DS; Alibhai SMH; Puts M
J Geriatr Oncol; 2023 Jan; 14(1):101397. PubMed ID: 36988104
[TBL] [Abstract][Full Text] [Related]
35. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
[TBL] [Abstract][Full Text] [Related]
36. A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study.
Pollock Y; Zhang L; Kenfield SA; Van Blarigan EL; Rodvelt T; Rabow M; Macaire G; Weinberg R; Topp K; Friedlander T; Lin A; Fong L; Kim W; Ma B; Hough J; Lee M; Paciorek A; Ryan CJ; Chan JM; Small E; Aggarwal R
Urol Oncol; 2021 Oct; 39(10):730.e9-730.e15. PubMed ID: 34304981
[TBL] [Abstract][Full Text] [Related]
37. Self-care Experiences of Advanced Prostate Cancer Survivors Who Underwent Androgen Deprivation Therapy.
Chien CH; Huang XY
Cancer Nurs; 2022 May-Jun 01; 45(3):190-200. PubMed ID: 33654010
[TBL] [Abstract][Full Text] [Related]
38. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
[TBL] [Abstract][Full Text] [Related]
39. Technology-Based Psychosocial Intervention to Improve Quality of Life and Reduce Symptom Burden in Men with Advanced Prostate Cancer: Results from a Randomized Controlled Trial.
Penedo FJ; Fox RS; Oswald LB; Moreno PI; Boland CL; Estabrook R; McGinty HL; Mohr DC; Begale MJ; Dahn JR; Flury SC; Perry KT; Kundu SD; Yanez B
Int J Behav Med; 2020 Oct; 27(5):490-505. PubMed ID: 31898309
[TBL] [Abstract][Full Text] [Related]
40. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study.
Zhang Z; Yang L; Xie D; Shi H; Li G; Yu D
Psychooncology; 2017 Dec; 26(12):2238-2244. PubMed ID: 28474429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
